Biotech company Exonhit has received an Institutional Review Board (IRB) approval to start a 160-patient pilot clinical trial to evaluate the clinical utility of AclarusDx, a blood-based test as a diagnostic tool for Alzheimer’s Disease (AD).

The new blood test is based on the compared analysis of AD patients’ transcriptome with that of healthy controls.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US-based pilot study will begin enrolling patients in November 2011 and the blood samples will be sent to Exonhit’s Paris facility for AclarusDx test analysis.

Exonhit Management Board president Loïc Maurel said the aim of the study is to provide physicians with a diagnostic tool that will help them identify patients at high risk of having AD and to prescribe a complete diagnostic workup.

The multicentre blind validation study in France has showed that the test demonstrated a sensitivity of 81% and a specificity of 67%.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact